17,261 trials
Rheumatoid Arthritis
Primary: Percent Change From Baseline (Week 6) in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Week 12 — -35.34; 5.80 percent change
Stage IV Melanoma
Primary: Median Time of Progression-free Survival — 2.20; 1.95 Months
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants
Cancer
Primary: Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 — 0; 4; 12; 0 participants
Respiratory Syncytial Virus Infections · Chronic Lung Disease and <= 24 Months of Age or · Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 19; 7; 11 participants
Cervical Dystonia
Primary: Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1 — 40.4; 41.5; 39.6; -10.3 Scores…
Malignant Ascites
Primary: The Proportion of Patients Who Achieved at Least a 4-fold Increase of Puncture/Paracentesis-free Interval Following Catumaxomab Relative to Their Pre-treatment Interval…
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
Pulmonary Disease, Chronic Obstructive
Primary: Maximum Plasma Concentration at Steady-state (Cmax,ss) — 2.81; 5.07; 10.5; 12.9 pg/ml — p=0.4423
Pain
Primary: Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing. — 36.7; 59.7; 55.6; 72.1 percentage of patients
Pulmonary Diseases · Neoplasms, Lung
Primary: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). — 0; 0…
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
Coronary Artery Disease · Angina, Unstable
Primary: Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment. — 301.0; 330.0; 354.0; 237.5 second
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain, 28 Days After Completion of the Primary Immunization Schedule With One of 3…
Primary Systemic Amyloidosis
Primary: Number of Participants With a Confirmed Hematologic Response — 0; 0; 0 participants